{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:08:39Z","timestamp":1791896919517,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejmech.2024.116855","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T21:16:43Z","timestamp":1725743803000},"page":"116855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Allosteric site identification, virtual screening and discovery of a sulfonamide Hsp110-STAT3 interaction inhibitor for the treatment of hypoxic pulmonary arterial hypertension"],"prefix":"10.1016","volume":"279","author":[{"given":"Congke","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhe","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116855_bib1","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMra2000348","article-title":"Pulmonary arterial hypertension","volume":"385","author":"Hassoun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116855_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2024.116855_bib3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","article-title":"A global view of pulmonary hypertension","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2024.116855_bib4","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension: a review","volume":"327","author":"Ruopp","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2024.116855_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12170-020-00663-3","article-title":"Management of pulmonary arterial hypertension","volume":"15","author":"Mayeux","year":"2021","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"10.1016\/j.ejmech.2024.116855_bib6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrd4623","article-title":"Strategies to increase nitric oxide signalling in cardiovascular disease","volume":"14","author":"Lundberg","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116855_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1183\/09031936.00078207","article-title":"Endothelin receptor antagonists in pulmonary arterial hypertension","volume":"31","author":"Dupuis","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2024.116855_bib8","doi-asserted-by":"crossref","first-page":"56S","DOI":"10.1016\/j.jacc.2004.02.036","article-title":"Prostanoid therapy for pulmonary arterial hypertension","volume":"43","author":"Badesch","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2024.116855_bib9","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2024.116855_bib10","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1378\/chest.15-0300","article-title":"Five-year outcomes of patients enrolled in the REVEAL registry","volume":"148","author":"Farber","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2024.116855_bib11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.healun.2019.12.013","article-title":"Risk assessment in pulmonary arterial hypertension: insights from the GRIPHON study","volume":"39","author":"Sitbon","year":"2020","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.ejmech.2024.116855_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-med-041717-085955","article-title":"New and emerging therapies for pulmonary arterial hypertension","volume":"70","author":"Spiekerkoetter","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2024.116855_bib13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","article-title":"Mechanisms of disease: pulmonary arterial hypertension","volume":"8","author":"Schermuly","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejmech.2024.116855_bib14","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1089\/ars.2018.7673","article-title":"Focus on early events: pathogenesis of pulmonary arterial hypertension development","volume":"31","author":"Rafikova","year":"2019","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejmech.2024.116855_bib15","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.drudis.2022.01.011","article-title":"An emerging strategy for targeted therapy of pulmonary arterial hypertension: vasodilation plus vascular remodeling inhibition","volume":"27","author":"Hu","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2024.116855_bib16","doi-asserted-by":"crossref","first-page":"15153","DOI":"10.1021\/acs.jmedchem.0c01093","article-title":"Targeted drugs for treatment of pulmonary arterial hypertension: past, present, and future perspectives","volume":"63","author":"Zheng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116855_bib17","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1002\/mco2.161","article-title":"Heat shock proteins: biological functions, pathological roles, and therapeutic opportunities","volume":"3","author":"Hu","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2024.116855_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101082","article-title":"Interdomain interactions dictate the function of the Candida albicans Hsp110 protein Msi3","volume":"297","author":"Li","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116855_bib19","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1038\/s41467-023-38220-2","article-title":"A first-in-class inhibitor of Hsp110 molecular chaperones of pathogenic fungi","volume":"14","author":"Hu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116855_bib20","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1515\/hsz-2018-0209","article-title":"Roles of the nucleotide exchange factor and chaperone Hsp110 in cellular proteostasis and diseases of protein misfolding","volume":"399","author":"Yakubu","year":"2018","journal-title":"Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116855_bib21","doi-asserted-by":"crossref","first-page":"21399","DOI":"10.1074\/jbc.M113.479253","article-title":"Hsp110 is a bona fide chaperone using ATP to unfold stable misfolded polypeptides and reciprocally collaborate with Hsp70 to solubilize protein aggregates","volume":"288","author":"Mattoo","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116855_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cell.2005.11.039","article-title":"Systems analyses reveal two chaperone networks with distinct functions in eukaryotic cells","volume":"124","author":"Albanese","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116855_bib23","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1091\/mbc.e09-09-0779","article-title":"Hsp110 chaperones control client fate determination in the hsp70-Hsp90 chaperone system","volume":"21","author":"Mandal","year":"2010","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ejmech.2024.116855_bib24","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1038\/emboj.2012.264","article-title":"Metazoan Hsp70 machines use Hsp110 to power protein disaggregation","volume":"31","author":"Rampelt","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2024.116855_bib25","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1161\/STROKEAHA.107.506188","article-title":"Targeted disruption of Hsp110\/105 gene protects against ischemic stress","volume":"39","author":"Nakamura","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.ejmech.2024.116855_bib26","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1128\/MCB.01332-06","article-title":"Hspa4l-deficient mice display increased incidence of male infertility and hydronephrosis development","volume":"26","author":"Held","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.116855_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/MIB.0000000000000244","article-title":"Involvement of heat shock protein a4\/apg-2 in refractory inflammatory bowel disease","volume":"21","author":"Adachi","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejmech.2024.116855_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12931-022-02124-4","article-title":"Knockdown of HSP110 attenuates hypoxia-induced pulmonary hypertension in mice through suppression of YAP\/TAZ-TEAD4 pathway","volume":"23","author":"Liu","year":"2022","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejmech.2024.116855_bib29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12931-023-02600-5","article-title":"Inhibition of Hsp110-STAT3 interaction in endothelial cells alleviates vascular remodeling in hypoxic pulmonary arterial Hypertension model","volume":"24","author":"Zhao","year":"2023","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejmech.2024.116855_bib30","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1021\/acs.jmedchem.9b00940","article-title":"Heat shock protein 90 Inhibitors: an update on achievements, challenges, and future directions","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116855_bib31","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.apsb.2020.01.018","article-title":"Modulation of protein fate decision by small molecules: targeting molecular chaperone machinery","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.116855_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax2277","article-title":"Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer","volume":"5","author":"Wang","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2024.116855_bib33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/med.21807","article-title":"Targeting the HSP90-CDC37-kinase chaperone cycle: a promising therapeutic strategy for cancer","volume":"42","author":"Wang","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2024.116855_bib34","doi-asserted-by":"crossref","first-page":"11215","DOI":"10.1021\/acs.jmedchem.0c01132","article-title":"Discovery of novel pyrazolo[3,4-b] pyridine derivatives with dual activities of vascular remodeling inhibition and vasodilation for the treatment of pulmonary arterial hypertension","volume":"63","author":"Hu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116855_bib35","doi-asserted-by":"crossref","first-page":"W427","DOI":"10.1093\/nar\/gkad303","article-title":"PASSer: fast and accurate prediction of protein allosteric sites","volume":"51","author":"Tian","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2024.116855_bib36","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1021\/acs.jcim.3c00336","article-title":"Binding site detection remastered: enabling fast, robust, and reliable binding site detection and descriptor calculation with DoGSite3","volume":"63","author":"Graef","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2024.116855_bib37","doi-asserted-by":"crossref","first-page":"W422","DOI":"10.1093\/nar\/gkae236","article-title":"ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support","volume":"52","author":"Fu","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2024.116855_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/wcms.1606","article-title":"Software update: the ORCA program system-version 5.0","volume":"12","author":"Neese","year":"2022","journal-title":"WIRES COMPUT MOL SCI"},{"key":"10.1016\/j.ejmech.2024.116855_bib39","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jcc.22885","article-title":"Multiwfn: a multifunctional wavefunction analyzer","volume":"33","author":"Lu","year":"2012","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2024.116855_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2022.107017","article-title":"TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats","volume":"145","author":"Zhao","year":"2022","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116855_bib41","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.bbagen.2017.05.006","article-title":"Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation","volume":"1861","author":"Goode","year":"2017","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.ejmech.2024.116855_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105523","article-title":"Tubocapsenolide A targets C-terminal cysteine residues of HSP90 to exert the anti-tumor effect","volume":"166","author":"Zhu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2024.116855_bib43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2015.10.002","article-title":"Allosteric small-molecule kinase inhibitors","volume":"156","author":"Wu","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2024.116855_bib44","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/13543784.2014.902934","article-title":"Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer","volume":"23","author":"Fasano","year":"2014","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2024.116855_bib45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2024.116855_bib46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41418-019-0343-4","article-title":"Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy","volume":"27","author":"Gozzi","year":"2020","journal-title":"Cell Death Differ."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424007360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424007360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T20:40:06Z","timestamp":1731271206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424007360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":46,"alternative-id":["S0223523424007360"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116855","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allosteric site identification, virtual screening and discovery of a sulfonamide Hsp110-STAT3 interaction inhibitor for the treatment of hypoxic pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116855","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116855"}}